NeuroGenetic Pharmaceuticals
Del Mar
About NeuroGenetic Pharmaceuticals
Neurogenetic Pharmaceuticals, Inc. (NGP) is a biopharmaceutical discovery and development company founded in 2009 which is focused on developing innovative drug therapies for use in the treatment of neurodegenerative disorders such as Alzheimer’s disease. Based in San Diego, Calif., the company’s next objective is to obtain an Investigational New Drug approval for its clinical candidate, NGP 555. This compound is expected to prevent the deposition of amyloid plaques in the brain, thereby precluding neuronal cell death and the dementia associated with AD. Future clinical trials will utilize specific ╬æ╬▓ biomarkers and/or brain scanning as an early diagnostic and to monitor drug efficacy in clinical trials. NGP licensed the GSM intellectual property from TPTX and expanded its portfolio to include issued patents in the US, Europe, China, India, Japan, Australia, and other countries.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $4.0M
- Last round: Grant (Nov 2015)
- Website: neurogeneticpharmaceuticals.com
- Phone: (858)735-5892
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/neurogenetic-pharmaceuticals-2779229 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.